Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vasopeptidase inhibitors.

M A Weber1

  • 1Office of Scientific Affairs, SUNY Downstate Medical College, State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 97, Brooklyn, NY 11203, USA. mweber@downstate.edu

Lancet (London, England)
|November 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fast, High-Fidelity Addressed Single-Qubit Gates Using Efficient Composite Pulse Sequences.

Physical review letters·2023
Same author

Robust Quantum Memory in a Trapped-Ion Quantum Network Node.

Physical review letters·2023
Same author

Erratum to "Second Consensus on Treatment of Patients Recently Diagnosed with Mild Hypertension and Low Cardiovascular Risk". [YMCD 45/10 (October 2020) 100653].

Current problems in cardiology·2021
Same author

[Certification in cardiology : Contra: The concept should be improved].

Herz·2018
Same author

Higgs physics at the CLIC electron-positron linear collider.

The European physical journal. C, Particles and fields·2017
Same author

[Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

Der Radiologe·2017

New vasopeptidase inhibitors offer dual action, lowering blood pressure and improving cardiovascular health in hypertension and heart failure models. Clinical trials show effectiveness across diverse populations, potentially surpassing current treatments.

Area of Science:

  • Cardiovascular Pharmacology
  • Drug Discovery
  • Hypertension Research

Background:

  • Vasopeptidase inhibitors represent a novel cardiovascular drug class.
  • They simultaneously inhibit neutral endopeptidase and angiotensin-converting enzyme (ACE).
  • This dual inhibition modulates vasodilatory peptides and angiotensin II production.

Purpose of the Study:

  • To evaluate the efficacy and safety of vasopeptidase inhibitors.
  • To assess their potential in treating hypertension, heart failure, and ischemic heart disease.
  • To compare their effectiveness against existing antihypertensive agents.

Main Methods:

  • Review of preclinical animal models for hypertension, heart failure, and ischemic heart disease.
  • Analysis of clinical studies in human hypertension and congestive heart failure.

Related Experiment Videos

  • Examination of safety profiles and side-effect frequencies, including angio-oedema and cough.

    • Main Results:

    • In animal models, vasopeptidase inhibitors reduced blood pressure across various hypertension types and showed benefits in heart failure and ischemic heart disease.
    • Human studies demonstrated effective blood pressure reduction irrespective of race or age.
    • Omapatrilat, a leading agent, exhibited greater efficacy than current ACE inhibitors and other antihypertensives, with positive effects in heart failure.

    Conclusions:

    • Vasopeptidase inhibitors show promise as effective treatments for hypertension and heart failure.
    • Their safety profile appears comparable to ACE inhibitors, though further data on side effects is needed.
    • Large-scale clinical endpoint trials are crucial to define their role alongside established therapies.